Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

Novo Nordisk (NVO) stock gains as its weight loss drug succeeds in Phase 3 trial for the liver disease, MASH hurting Eli ...

Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Bagsværd, Denmark Tuesday, November 5, 2024, 10:00 Hrs [IST] ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptanceCompany also announces FDA End-of-Phase 2 in-person meeting ...

However, a phase 2 trial in the setting ran into challenges ... Editor's note: This story was updated at 10 am on Oct. 3 to include comments from Takeda.

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer ... high-risk stage 2b to 4 melanoma. The new phase 2 trial is another endorsement of the potential of V940 ...

It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with updates.

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

The 321-subject trial is comparing the anti-CD40L antibody ... Other candidates include anti-BDCA2 antibody litifilimab in phase 3 for SLE and phase 2 for cutaneous lupus erythematosus (CLE ...